Impact Factor 3.675

The 2nd most cited open-access journal in Endocrinology & Metabolism

This article is part of the Research Topic

Bone: Endocrine Target and Organ

Correction ARTICLE

Front. Endocrinol., 20 July 2017 | https://doi.org/10.3389/fendo.2017.00172

Corrigendum: Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review

  • 1Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
  • 2Department of Endocrinology, Aalborg University, Aalborg, Denmark

A corrigendum on

Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review
by Leere JS, Karmisholt J, Robaczyk M and Vestergaard P. Front Endocrinol (2017) 8:79. doi:10.3389/fendo.2017.00079

Missing Supplementary Information

In the original article, there was a mistake in the published supplementary material. The literature search string as mentioned in the section “Literature Search and Selection Strategy” never appeared in the published material. The search string as applied in Medline appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Ovid Technologies, Inc. Email Service

Database: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)<1946 to Present>

Search Strategy:

1 Hyperparathyroidism, Primary/dt [Drug Therapy] (99)

2 Hyperparathyroidism, Primary/(2211)

3 Parathyroid adenom*.mp. (4188)

4 (Primary adj2 Hyperparathyr*).mp. (9043)

5 2 or 3 or 4 (11256)

6 exp Diphosphonates/(22931)

7 bisphosphonate*.mp. (14211)

8 diphosphonat*.mp. (17321)

9 bisphosphonic*.mp. (152)

10 clodron*.mp. (2326)

11 alendron*.mp. (4714)

12 etidron*.mp. (3123)

13 ibandron*.mp. (1063)

14 incadron*.mp. (78)

15 medron*.mp. (4405)

16 minodron*.mp. (104)

17 neridron*.mp. (94)

18 olpadron*.mp. (77)

19 pamidron*.mp. (2920)

20 risedron*.mp. (1775)

21 tiludron*.mp. (156)

22 zoledron*.mp. (4145)

23 cinacalcet.mp. (1071)

24 Cinacalcet Hydrochloride/(735)

25 "amg 073".mp. (24)

26 amg073.mp. (0)

27 krn 1493.mp. (3)

28 krn1493.mp. (4)

29 mimpara.mp. (20)

30 parareg.mp. (0)

31 regpara.mp. (1)

32 sensipar.mp. (30)

33 exp Isoflavones/(15928)

34 ipriflavone.mp. (268)

35 Denosumab/(925)

36 denosumab.mp. (1712)

37 amg 162.mp. (33)

38 amg162.mp. (3)

39 amgiva.mp. (0)

40 prolia.mp. (32)

41 xgeva.mp. (16)

42 blosozumab.mp. (14)

43 ly 2541546.mp. (0)

44 ly2541546.mp. (1)

45 romosozumab.mp. (45)

46 amg 785.mp. (27)

47 amg785.mp. (0)

48 cdp 7851.mp. (0)

49 cdp7851.mp. (3)

50 odanacatib.mp. (156)

51 ("mk 0822" or mk0822 or mk822 or mk 822).mp. (5)

52 etelcalcetide.mp. (5)

53 (amg 416 or amg416).mp. (12)

54 (kai 4169 or kai4169).mp. (1)

55 (ono 5163 or ono5163).mp. (0)

56 telcalcetide.mp. (0)

57 velcalcetide.mp. (4)

58 or/6-57 (49081)

59 5 and 58 (459)

60 1 or 59 (491)

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: primary hyperparathyroidism, parathyroid adenoma, medical treatment, drug therapy, bisphosphonates, cinacalcet

Citation: Leere JS, Karmisholt J, Robaczyk M and Vestergaard P (2017) Corrigendum: Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review. Front. Endocrinol. 8:172. doi: 10.3389/fendo.2017.00172

Received: 30 June 2017; Accepted: 04 July 2017;
Published: 20 July 2017

Edited and Reviewed by: Patrizia D’Amelio, University of Turin, Italy

Copyright: © 2017 Leere, Karmisholt, Robaczyk and Vestergaard. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Julius Simoni Leere, j.leere@rn.dk